Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cells.
about
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta roleHypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to HypoxiaThe role of NANOG transcriptional factor in the development of malignant phenotype of cancer cellsConcise Review: NANOG in Cancer Stem Cells and Tumor Development: An Update and Outstanding QuestionsHypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellsTranscriptional Regulation of Human NANOG by Alternate Promoters in Embryonic Stem Cells.Regulation of NANOG in cancer cells.Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer modelsExpression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+ T cells.Gain of HIF-1α under normoxia in cancer mediates immune adaptation through the AKT/ERK and VEGFA axes.Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment.Cutting Edge: NANOG Activates Autophagy under Hypoxic Stress by Binding to BNIP3L Promoter.Targeting PD-1/PD-L1 in lung cancer: current perspectives.Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression.Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells.NANOG signaling promotes metastatic capability of immunoedited tumor cells.Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy
P2860
Q26769734-D498E3A5-26CC-46ED-AB7C-4D21B0A011ABQ28085029-BC496B46-FB00-4C40-9C2F-5E03C2C471D6Q28085385-C410ABD1-A2CF-4D97-BB90-9451F607AD65Q28088370-0D9B29E2-A21C-4737-8265-9FD098806DB2Q28393898-718A53B5-D3D1-43BD-9D61-9F8CF5BC5E20Q33957023-07438CB0-0EC0-4EFE-A789-145E07EC750AQ34478004-8BDF8B14-D29B-4819-BE7D-2310287EE00EQ34782683-9C541073-636B-410F-AD49-0BD6BDE8BCDCQ35065243-775FFEA2-D902-4753-B235-C923D52F65D2Q35178345-EF3F0F7E-A214-49E4-94EE-EF06CE97D57EQ37698857-FAFC9714-CCCE-4BF0-8457-1C87EBE96219Q38246724-D4AFE682-BC5E-40E0-B3ED-57AE9CCF1D90Q38721023-6D3E3EBF-1A86-4FB1-A692-6FD6B0B53868Q38956294-0750A2A1-7D2A-4AEC-8C67-70CCB7087F8DQ38984559-ED47991D-37D1-4933-B5DB-93AB1ED2F5FAQ39198840-5EA704DA-DF98-4BA4-9FA6-44A1AB901BE4Q41300653-8194CBB5-2199-4342-9562-F89E08169D68Q55260560-11AB2124-1B87-41DB-9EAC-5D4B8E42AE68Q58748151-58398C77-C68F-433F-88C1-888869BAEE5C
P2860
Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cells.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Hypoxia-dependent inhibition o ...... NOG induction in target cells.
@en
Hypoxia-dependent inhibition o ...... NOG induction in target cells.
@nl
type
label
Hypoxia-dependent inhibition o ...... NOG induction in target cells.
@en
Hypoxia-dependent inhibition o ...... NOG induction in target cells.
@nl
prefLabel
Hypoxia-dependent inhibition o ...... NOG induction in target cells.
@en
Hypoxia-dependent inhibition o ...... NOG induction in target cells.
@nl
P2093
P356
P1476
Hypoxia-dependent inhibition o ...... NOG induction in target cells.
@en
P2093
Aude Mallavialle
Fathia Mami-Chouaib
Filippo Rosselli
Jessica Lauriol
Meriem Hasmim
Muhammad Zaeem Noman
Salem Chouaib
P304
P356
10.4049/JIMMUNOL.1101011
P407
P577
2011-09-12T00:00:00Z